[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CO2017011017A2 - Azabenzimidazoles y su uso como moduladores del receptor ampa - Google Patents

Azabenzimidazoles y su uso como moduladores del receptor ampa

Info

Publication number
CO2017011017A2
CO2017011017A2 CONC2017/0011017A CO2017011017A CO2017011017A2 CO 2017011017 A2 CO2017011017 A2 CO 2017011017A2 CO 2017011017 A CO2017011017 A CO 2017011017A CO 2017011017 A2 CO2017011017 A2 CO 2017011017A2
Authority
CO
Colombia
Prior art keywords
azabenzimidazoles
modulators
ampa receptor
formula
compounds
Prior art date
Application number
CONC2017/0011017A
Other languages
English (en)
Inventor
Cynthia G B Berry
Gang Chen
Fabrice Loic Jourdan
Terry Patrick Lebold
David Wei Lin
Piñón Miguel Angel Pena
Suchitra Ravula
Bradley M Savall
Devin M Swanson
Dongpei Wu
Wei Zhang
Michael K Ameriks
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CO2017011017A2 publication Critical patent/CO2017011017A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

RESUMEN En la presente invención se proporcionan compuestos de la Fórmula (I) y sales farmacéuticamente aceptables, N-óxidos o solvatos de estos. (I) Además, en la presente invención se proporcionan composiciones farmacéuticas que comprenden compuestos de la Fórmula (I) y métodos para usar los compuestos de la Fórmula (I).
CONC2017/0011017A 2015-04-29 2017-10-27 Azabenzimidazoles y su uso como moduladores del receptor ampa CO2017011017A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562154313P 2015-04-29 2015-04-29
PCT/US2016/029801 WO2016176460A1 (en) 2015-04-29 2016-04-28 Azabenzimidazoles and their use as ampa receptor modulators

Publications (1)

Publication Number Publication Date
CO2017011017A2 true CO2017011017A2 (es) 2018-03-20

Family

ID=56008859

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0011017A CO2017011017A2 (es) 2015-04-29 2017-10-27 Azabenzimidazoles y su uso como moduladores del receptor ampa

Country Status (39)

Country Link
US (4) US11312712B2 (es)
EP (3) EP4144736A1 (es)
JP (2) JP6800886B2 (es)
KR (2) KR102782808B1 (es)
CN (1) CN107835814B (es)
AR (1) AR104447A1 (es)
AU (2) AU2016255434C1 (es)
BR (2) BR122023023802A2 (es)
CA (1) CA2983826A1 (es)
CO (1) CO2017011017A2 (es)
CR (1) CR20170484A (es)
CY (1) CY1124059T1 (es)
DK (1) DK3288940T5 (es)
EA (1) EA033281B1 (es)
EC (1) ECSP17074645A (es)
ES (1) ES2865330T3 (es)
GT (1) GT201700231A (es)
HR (1) HRP20210403T1 (es)
HU (1) HUE053943T2 (es)
IL (1) IL254848B (es)
JO (1) JO3654B1 (es)
LT (1) LT3288940T (es)
MA (1) MA41988B1 (es)
MD (1) MD3288940T2 (es)
MX (1) MX376113B (es)
MY (1) MY194104A (es)
NI (1) NI201700129A (es)
PH (1) PH12017501816B1 (es)
PL (1) PL3288940T3 (es)
PT (1) PT3288940T (es)
RS (1) RS61688B1 (es)
SG (1) SG11201708190UA (es)
SI (1) SI3288940T1 (es)
SM (1) SMT202100222T1 (es)
TW (1) TWI706952B (es)
UA (1) UA120304C2 (es)
UY (1) UY36654A (es)
WO (1) WO2016176460A1 (es)
ZA (1) ZA201708065B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY194104A (en) 2015-04-29 2022-11-11 Janssen Pharmaceutica Nv Azabenzimidazoles and their use as ampa receptor modulators
JP6800885B2 (ja) * 2015-04-29 2020-12-16 ヤンセン ファーマシューティカ エヌ．ベー． イミダゾピラジン及びピラゾロピリミジン、並びにａｍｐａ受容体調節物質としてのこれらの使用
CN118853581A (zh) 2017-06-21 2024-10-29 美商生物细胞基因治疗有限公司 嵌合抗原受体(CARs)、组合物及其使用方法
CN107383004B (zh) * 2017-07-05 2020-04-17 浙江大学 2-氨基咪唑并吡啶类衍生物及制备和应用
CN111315735B (zh) 2017-09-04 2024-03-08 C4医药公司 二氢苯并咪唑酮
EP3693360B1 (en) * 2017-10-06 2023-12-13 Takeda Pharmaceutical Company Limited Heterocyclic compounds
ES2976515T3 (es) 2018-10-05 2024-08-02 Annapurna Bio Inc Compuestos y composiciones para tratar afecciones asociadas con la actividad del receptor APJ
EP3873905A4 (en) * 2018-10-30 2022-08-17 Repare Therapeutics Inc. COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, METHODS FOR PREPARING COMPOUNDS AND THEIR USE AS KINASE ATR INHIBITORS
CR20220068A (es) * 2019-07-22 2022-06-30 Repare Therapeutics Inc Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr
EP4263523A2 (en) * 2020-12-16 2023-10-25 IFM Due, Inc. Compounds and compositions for treating conditions associated with sting activity
CN114591338B (zh) * 2022-03-31 2023-05-09 苏州欧康维视生物科技有限公司 一种Syk和VEGFR2双靶点抑制剂的制备方法及其用途
CN115304599A (zh) * 2022-09-20 2022-11-08 浙大宁波理工学院 一种3-溴-6-异丙基-1氢-哌咯[2，3-b]并吡啶及其制备方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55167282A (en) 1979-06-12 1980-12-26 Fujisawa Pharmaceut Co Ltd Piperazine derivative or its salt and its preparation
CN1051313A (zh) 1990-11-07 1991-05-15 鞍山市振东工业尼龙厂 尼龙球磨罐及其热装工艺
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
TW251284B (es) * 1992-11-02 1995-07-11 Pfizer
KR970701182A (ko) * 1994-02-10 1997-03-17 스피겔 알렌 제이 벤조다이아제핀 수용체 부위의 작용물질 및 길항물질로서의 5-헤테로아릴인돌 유도체(5-heteroarylindole derivatives as benzodiazepine receptor site agonists and antagonists)
US5565483A (en) 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
UA54403C2 (uk) 1996-10-01 2003-03-17 Н'Юросерч А/С Похідні індол-2,3-діон-3-оксиму, фармацевтична композиція, спосіб лікування розладу чи захворювання ссавців, у тому числі людини та спосіб одержання похідних індол-2,3-діон-3-оксиму
AU2931099A (en) 1998-03-06 1999-09-20 Janssen Pharmaceutica N.V. Crf antagonistic pyrazolo(4,3-b)pyridines
DE19812331A1 (de) 1998-03-20 1999-09-23 Merck Patent Gmbh Piperidinderivate
EP1100504A2 (en) * 1998-07-02 2001-05-23 Eisai Co., Ltd. Pharmaceutical compositions and their uses for treatment of demyelinating disorders
JP2002533360A (ja) 1998-12-31 2002-10-08 スージェン・インコーポレーテッド 蛋白質キナーゼ活性を調節するためおよび癌の化学療法において用いるための３−ヘテロアリーリデニル−２−インドリノン化合物
GB0018473D0 (en) 2000-07-27 2000-09-13 Merck Sharp & Dohme Therapeutic agents
EP1309577A2 (en) 2000-08-11 2003-05-14 Eli Lilly And Company Heterocyclic sulfonamide derivatives and their use for potentiating glutamate receptor function
US6548576B1 (en) 2001-11-07 2003-04-15 Bourns, Inc. Epoxy formulation adapted to be used in conjunction with no-lead solder in electronic components
GT200500185A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
ATE532783T1 (de) * 2004-09-03 2011-11-15 Merck Serono Sa Pyridinmethylenzolidinone und ihre verwendung als phosphoinositid-hemmer
CN101321736B (zh) 2005-09-30 2012-04-04 葛兰素集团有限公司 对m1受体具有活性的化合物及其在医药中的用途
WO2007135529A2 (en) * 2006-05-23 2007-11-29 Pfizer Products Inc. Azabenzimidazolyl compounds as mglur2 potentiators
DE602007013450D1 (de) 2006-11-03 2011-05-05 Glaxo Group Ltd Verbindungen, die den ampa-rezeptor verstärken, und deren anwendung in der medizin
WO2008113795A1 (en) 2007-03-20 2008-09-25 Glaxo Group Limited Compounds which potentiate ampa receptor and uses thereof in medicine
GB0711089D0 (en) 2007-06-08 2007-07-18 Glaxo Group Ltd Compounds
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
WO2009067607A2 (en) 2007-11-20 2009-05-28 Memory Pharmaceuticals Corporation Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders
JP2011506335A (ja) * 2007-12-06 2011-03-03 シェーリング コーポレイション γ−セクレターゼ調節剤
TW201012803A (en) * 2008-06-06 2010-04-01 Organon Nv Heterocyclic derivatives
WO2010005528A2 (en) * 2008-06-30 2010-01-14 Ironwood Pharmaceuticals Incorporated Pyrrolopyridine carboxylic acid derivatives
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
GB0822425D0 (en) 2008-12-09 2009-01-14 Glaxo Group Ltd Compounds
GB0822981D0 (en) 2008-12-17 2009-01-21 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
WO2011056985A2 (en) 2009-11-04 2011-05-12 Gilead Sciences, Inc. Substituted heterocyclic compounds
PH12012501621A1 (en) 2010-02-11 2012-10-22 Univ Vanderbilt Pyrazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US8765784B2 (en) * 2010-06-09 2014-07-01 Merck Sharp & Dohme Corp. Positive allosteric modulators of MGLUR2
TWI546302B (zh) 2010-06-24 2016-08-21 武田藥品工業股份有限公司 稠合雜環化合物
SG187656A1 (en) 2010-08-10 2013-03-28 Takeda Pharmaceutical Heterocyclic compound and use thereof
US8993779B2 (en) 2010-08-12 2015-03-31 Merck Sharp & Dohme Corp. Positive allosteric modulators of MGLUR2
MX2014005304A (es) 2011-10-31 2015-03-20 Xenon Pharmaceuticals Inc Biaril eter sulfonamidas y su uso como agentes terapeuticos.
WO2013130501A1 (en) * 2012-03-01 2013-09-06 The Board Of Regents Of The University Of Texas System Bivalent ampa receptor positive allosteric modulators
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
JO3225B1 (ar) * 2012-11-27 2018-03-08 Lilly Co Eli 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8
SG11201505878UA (en) 2013-02-19 2015-09-29 Pfizer Azabenzimidazole compounds as inhibitors of pde4 isozymes for the treatment of cns and other disorders
TW201609719A (zh) 2014-05-28 2016-03-16 美國禮來大藥廠 作為ＴＡＲＰ－γ８依賴性ＡＭＰＡ受體拮抗劑之６－經取代－３Ｈ－１，３－苯并噻唑－２－酮化合物
WO2016161282A1 (en) 2015-04-03 2016-10-06 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
MY194104A (en) 2015-04-29 2022-11-11 Janssen Pharmaceutica Nv Azabenzimidazoles and their use as ampa receptor modulators
WO2018080918A1 (en) 2016-10-26 2018-05-03 Janssen Pharmaceutica Nv 3-aryl-2h-pyrazolo[4,3-b]pyridine compounds and their use as ampa receptor modulators
AU2017350688B2 (en) 2016-10-26 2021-04-01 Rapport Therapeutics, Inc. Fused azaheterocyclic compounds and their use as AMPA receptor modulators
AU2017350689B2 (en) 2016-10-26 2021-05-20 Rapport Therapeutics, Inc. Fused bicylic pyridine compounds and their use as AMPA receptor modulators
WO2019198692A1 (en) 2018-04-09 2019-10-17 Raqualia Pharma Inc. Fused cyclic urea derivatives as crhr2 antagonist
US20220098205A1 (en) 2019-02-01 2022-03-31 Hanmi Pharm. Co., Ltd. Imidazopyridine derivative compounds and use of same

Also Published As

Publication number Publication date
AU2016255434C1 (en) 2021-09-23
EA033281B1 (ru) 2019-09-30
NZ736057A (en) 2023-08-25
EP3288940B1 (en) 2021-02-24
AU2020210231A1 (en) 2020-08-20
CA2983826A1 (en) 2016-11-03
EP3901153A1 (en) 2021-10-27
KR20240017991A (ko) 2024-02-08
IL254848B (en) 2021-01-31
WO2016176460A1 (en) 2016-11-03
MA41988B1 (fr) 2021-03-31
MX376113B (es) 2025-03-07
US12304908B2 (en) 2025-05-20
BR112017023147B1 (pt) 2024-04-30
ZA201708065B (en) 2019-09-25
HRP20210403T1 (hr) 2021-10-29
NI201700129A (es) 2019-05-10
US11312712B2 (en) 2022-04-26
US20210284641A1 (en) 2021-09-16
US12139485B2 (en) 2024-11-12
BR122023023802A2 (pt) 2023-12-26
PT3288940T (pt) 2021-04-30
KR102782808B1 (ko) 2025-03-14
JP7026194B2 (ja) 2022-02-25
UA120304C2 (uk) 2019-11-11
HUE053943T2 (hu) 2021-08-30
EP3288940B9 (en) 2021-07-21
TW201708217A (zh) 2017-03-01
MX2017013886A (es) 2018-03-12
JO3654B1 (ar) 2020-08-27
PH12017501816B1 (en) 2023-07-19
US20230114165A1 (en) 2023-04-13
EA201792374A1 (ru) 2018-05-31
JP6800886B2 (ja) 2020-12-16
JP2021042230A (ja) 2021-03-18
AR104447A1 (es) 2017-07-19
KR20170140382A (ko) 2017-12-20
AU2020210231B2 (en) 2021-07-22
MD3288940T2 (ro) 2021-08-31
DK3288940T3 (da) 2021-05-25
JP2018518462A (ja) 2018-07-12
PH12017501816A1 (en) 2018-04-23
ECSP17074645A (es) 2018-02-28
AU2016255434B2 (en) 2020-05-14
HK1252249A1 (en) 2019-05-24
SMT202100222T1 (it) 2021-05-07
SG11201708190UA (en) 2017-11-29
BR112017023147A2 (pt) 2018-07-10
TWI706952B (zh) 2020-10-11
PL3288940T3 (pl) 2021-07-12
CY1124059T1 (el) 2022-05-27
US20180118740A1 (en) 2018-05-03
UY36654A (es) 2016-10-31
AU2016255434A1 (en) 2017-10-26
US12145934B2 (en) 2024-11-19
CN107835814A (zh) 2018-03-23
CN107835814B (zh) 2021-07-23
NZ774642A (en) 2024-09-27
SI3288940T1 (sl) 2021-07-30
MA41988A (fr) 2018-07-03
IL254848A0 (en) 2017-12-31
GT201700231A (es) 2018-12-20
ES2865330T3 (es) 2021-10-15
DK3288940T5 (da) 2021-09-20
LT3288940T (lt) 2021-05-10
EP4144736A1 (en) 2023-03-08
RS61688B1 (sr) 2021-05-31
CR20170484A (es) 2018-02-26
EP3288940A1 (en) 2018-03-07
MY194104A (en) 2022-11-11
US20230110576A1 (en) 2023-04-13

Similar Documents

Publication Publication Date Title
CO2017011017A2 (es) Azabenzimidazoles y su uso como moduladores del receptor ampa
MX2017013874A (es) Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa.
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
MX380829B (es) Derivados de quinoxalina útiles como amortiguadaores de receptor del factor de crecimiento de fibroblastos (fgfr) cinasa.
CR20170384A (es) Derivados de nucleosidos sustituidos utiles como agentes antineoplasicos
CR20150524A (es) Compuestos de heteroarilo y sus usos
MX2015011514A (es) Compuestos de heteroarilo y sus usos.
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
UY35485A (es) Compuestos heterocíclicos y usos de los mismos
CL2017003107A1 (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
ECSP16074478A (es) Compuestos novedosos
ECSP17069696A (es) Compuestos novedosos
MX2017000183A (es) Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides.
CO2019004164A2 (es) Compuestos de piridina bicíclicos fusionados y su uso como moduladores de receptores ampa
MX378389B (es) Compuestos de bencimidazolona y benzotiazolona y su uso como moduladores del receptor ampa.
CL2020001062A1 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos.
CO2020004977A2 (es) Compuestos bicíclicos para su uso como inhibidores de la ripi quinasa
UY36117A (es) Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas.
CO2019004143A2 (es) Compuestos azaheterocíclicos fusionados y su uso como moduladores de los receptores ampa
ECSP16074482A (es) Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina
ECSP18056196A (es) Derivados de indano
MX2017013885A (es) Compuestos de indolona y su uso como moduladores del receptor ampa.
CR20140051A (es) Compuestos de tiazol y oxazol de bencen-sulfonamida